L. E. Raez

Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): A phase 2 study

M. Fanucchi, Frank V. Fossella, Panos Fidias et al. · Journal of Clinical Oncology · 2005 · 45 citations

Pathology, Pharmacotherapy, Arm B +18

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

Chandra P. Belani, John Nemunaitis, Abraham Chachoua et al. · Cancer Biology & Therapy · 2013 · 36 citations · Full text

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer

Suresh S. Ramalingam, Ahmad A. Tarhini, Dwight E. Heron et al. · Lung Cancer · 2013 · 21 citations

Chest Radiotherapy, Consolidation Chemotherapy, Medicine +8

Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas

L. E. Raez, Virginia K. Langmuir, K. Tolba et al. · Journal of Clinical Oncology · 2007 · 16 citations

Glycolytic Inhibitor, Docetaxel Chemotherapy, Pharmacotherapy +18

Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial

Trevor Feinstein, L. E. Raez, Kiran K. Rajasenan et al. · Journal of Clinical Oncology · 2008 · 14 citations

Neoadjuvant Therapy, Immunology, Pathology +22